Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and
Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the
treatment of hormone refractory prostate cancer. The investigators will determine the
tolerable dose of (oral) vinorelbine in combination with (oral) estramustine, and evaluate
the efficacy of this treatment for patients with hormone-refractory prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center